Document Detail

Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.
MedLine Citation:
PMID:  20008091     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To investigate the role of HLA-G in AS.
METHODS: Serum levels of soluble HLA-G (sHLA-G) were measured in 80 AS patients and 30 healthy controls. The expression of HLA-G on the peripheral blood mononuclear cell (PBMC) surface was investigated in the same 80 AS patients and 40 healthy controls by flow cytometry. The response of HLA-G after 3 months of TNF-alpha blocker therapy (adalimumab) was evaluated in 14 AS patients. We evaluated Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Patient Global Score (BAS-G), physical mobility, ESR and CRP levels.
RESULTS: Serum levels of sHLA-G were significantly lower in 80 AS patients than 30 healthy controls [mean (s.d.) 22.47 (26.8) vs 34.78 (32.01) U/ml, P = 0.028], and correlated significantly with modified Schober index (r = 0.326; P = 0.009), chest expansion (r = 0.319; P = 0.011), lateral lumbar flexion (r = 0.377; P = 0.002), cervical rotation (r = 0.396; P = 0.004), whereas inversely correlated with fingertip-to-floor distance (r = -0.282; P = 0.026) and tragus-to-wall distance (r = -0.270; P = 0.031). The expression of HLA-G on PBMCs was significantly higher in 80 AS patients than 40 healthy controls [mean (s.d.) 18.5 (6.10)% vs 15.41 (4.84)%; P = 0.012], and correlated significantly with ESR (r = 0.421; P < 0.001) and CRP (r = 0.419; P < 0.001). The expression of HLA-G on PMBCs decreased significantly after 3 months of adalimumab therapy [third month vs baseline, 13.46 (5.38)% vs 19.87 (7.31)%; P = 0.016].
CONCLUSIONS: Lower serum levels of sHLA-G contribute to susceptibility to AS, and predispose to poor spinal mobility. The expression of HLA-G on PMBCs is up-regulated in AS, correlates with acute phase reactants and decreases after TNF-alpha blocker therapy, suggesting an index of disease activity.
Chun-Hsiung Chen; Hsien-Tzung Liao; Hung-An Chen; Chin-Hsiu Liu; Toong-Hua Liang; Chin-Tien Wang; Chang-Youh Tsai; Chung-Tei Chou
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-12-11
Journal Detail:
Title:  Rheumatology (Oxford, England)     Volume:  49     ISSN:  1462-0332     ISO Abbreviation:  Rheumatology (Oxford)     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-01-14     Completed Date:  2010-12-07     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  100883501     Medline TA:  Rheumatology (Oxford)     Country:  England    
Other Details:
Languages:  eng     Pagination:  264-70     Citation Subset:  AIM; IM    
Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antirheumatic Agents / therapeutic use*
Biological Markers / blood
C-Reactive Protein / metabolism
Follow-Up Studies
HLA Antigens / blood*
HLA-G Antigens
Histocompatibility Antigens Class I / blood*
Leukocytes, Mononuclear / immunology
Middle Aged
Severity of Illness Index
Spondylitis, Ankylosing / drug therapy,  immunology*,  physiopathology
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antirheumatic Agents; 0/Biological Markers; 0/HLA Antigens; 0/HLA-G Antigens; 0/Histocompatibility Antigens Class I; 0/Tumor Necrosis Factor-alpha; 9007-41-4/C-Reactive Protein; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Axillary artery as alternative site of cannulation for redo port-access assisted minimaly invasive m...
Next Document:  First-line DMARD choice in early rheumatoid arthritis--do prognostic factors play a role?